AD/PD 2022 | The potential of vaccination for neurodegenerative disease

Johanne Kaplan, PhD, ProMIS™ Neurosciences, Inc., Cambridge, MA, explains the potential of vaccines with regards to neurodegenerative diseases. Current treatments such as antibodies require frequent administration, whereas a vaccine would only need a relatively low number of administrations to offer long term benefits. With future progress in the field of biomarkers it may eventually be possible during routine blood work for a clinician to offer a preventive vaccine to patients based on biomarker indications of increased risk. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.